^
Association details:
| Biomarker: | TP53 mutation + FGFR2 rearrangement |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Lytgobi (futibatinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
54P - Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/other rearrangements: Subgroup analyses of a phase II study (FOENIX-CCA2)
Published date:
09/14/2020
Excerpt:
Pts received oral futibatinib 20 mg 1x/day until PD/intolerance...In pts with confirmed FGFR2 alterations, ORR was 36.2% (21/58 fusions) and 44.4% (4/9 rearrangements). ORR was 33.3% in pts with FGFR2-BICC1. Best overall response in pts with comutations of interest is shown in the table below. These interim data demonstrate manageable AEs and efficacy of futibatinib in iCCA with FGFR2 fusions/other rearrangements. Responses were observed across pt subgroups, including those with common FGFR2 fusions, comutations, and poor prognostic factors. Best overall response in pts with comutations of interest is shown in the table below.
Trial ID:
